Table 5 Changes in treatment pattern by patients
Sunitinib 251 | Sorafenib 62 | Pazopanib 56 | Everolimus 70 | Temsirolimus 37 | Bevacizumab 5 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pre 143 | Post 108 | Pre 43 | Post 19 | Pre 1 | Post 55 | Pre 34 | Post 36 | Pre 19 | Post 18 | Pre 4 | Post 1 | |
Number of cycles administered | ||||||||||||
Median (Q1–Q3) | 4.0 (2.0–5.0) | 4.0 (2.0–5.0) | 3.0 (2.0–5.0) | 3.0 (2.0–8.0) | 1.0 (1.0–1.0) | 3.0 (2.0–5.0) | 3.0 (2.0–5.0) | 4.0 (2.0–6.0) | 2.0 (1.0–4.0) | 2.5 (2.0–4.0) | 3.5 (2.5–4.5) | 10.0 (10.0–10.0) |
*Treatment modification, n cycles (%) | ||||||||||||
Dose reduction | 24 (16.8) | 16 (14.8) | 4 (9.3) | 1 (5.3) | 0 (0.0) | 4 (7.3) | 1 (2.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Dose interruption | 8 (5.6) | 9 (8.3) | 2 (4.7) | 2 (10.5) | 0 (0.0) | 4 (7.3) | 3 (8.8) | 4 (11.1) | 1 (5.3) | 1 (5.6) | 0 (0.0) | 0 (0.0) |
Treatment discontinuation | 6 (4.2) | 5 (4.6) | 3 (7.0) | 0 (0.0) | 0 (0.0) | 5 (9.1) | 0 (0.0) | 3 (8.3) | 2 (10.5) | 2 (11.1) | 0 (0.0) | 0 (0.0) |
Dose increased | 0 (0.0) | 0 (0.0) | 1 (2.3) | 2 (10.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |